Selective RET tyrosine kinase inhibitors demonstrated striking clinical efficacy in lung and thyroid cancers with RET gene mutations or fusion with an overall response rate as high as 70% among treatment-naive patients (2). The gene discussed is RET; the disease is thyroid gland carcinoma.